Overview
NBIX market data
Price History
NBIX price chart
Valuation & Profitability
- P/E (TTM)
- 23.56 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $4.67 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.40 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 20.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $122.14 – $186.12 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $16.6B · P/B 4.35 · P/S 4.93.
Company News
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182Benzinga · Aug 13, 2026, 2:43 PM
What's Going On With Neurocrine Biosciences Stock On Wednesday?Benzinga · Aug 12, 2026, 3:57 PM
Neurocrine Biosciences Announces Publication Of Its KINCET-PRO Phase 4 Study Results Showing That Once-Daily INGREZZA Capsules Led To Substantial And Sustained Improvements In Patient-Reported Quality Of Life And FunctionalityBenzinga · Aug 12, 2026, 12:37 PM
Neurocrine Biosciences Initiates Phase 1 First-In-Human Clinical Study Evaluating NBIP-'1968, Investigational GLP-1/GIP/Glucagon Receptor Triple Agonist Being Developed As Therapy For ObesityBenzinga · Aug 7, 2026, 12:33 PM
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026Globenewswire Inc · Aug 7, 2026, 11:00 AM
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $210Benzinga · Aug 3, 2026, 9:25 PM
Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $213Benzinga · Aug 3, 2026, 2:06 PM
Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $194Benzinga · Aug 3, 2026, 1:08 PM
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $249Benzinga · Jul 31, 2026, 8:54 PM
RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $198Benzinga · Jul 31, 2026, 7:23 PM